We investigated in vitro and in vivo combination effects of GPR119 agonists with TKIs in breast cancer and hepatoma cells, and clarified the mechanistic basis for the anticancer effects of GPR119 agonists, focusing on autophagy inhibition. Here, GPR119 is linked to hepatocellular carcinoma.